Spinal muscular atrophy (SMA), an autosomal recessive disease caused by a decrease in levels of the survival motor neuron (SMN) protein, is the most common genetic cause of infant mortality. Although neuromuscular pathology is the most severe feature of SMA, other organs and tissues, including the heart, are also known to be affected in both patients and animal models. Here, we provide new insights into changes occurring in the heart, predominantly at pre-and early symptomatic ages, in the Taiwanese mouse model of severe SMA. Thinning of the interventricular septum and dilation of the ventricles occurred at pre-and early symptomatic ages. However, the left ventricular wall was significantly thinner in SMA mice from birth, occurring prior to any overt neuromuscular symptoms. Alterations in collagen IV protein from birth indicated changes to the basement membrane and contributed to the abnormal arrangement of cardiomyocytes in SMA hearts. This raises the possibility that developmental defects, occurring prenatally, may contribute to cardiac pathology in SMA. In addition, cardiomyocytes in SMA hearts exhibited oxidative stress at pre-symptomatic ages and increased apoptosis during early symptomatic stages of disease. Heart microvasculature was similarly decreased at an early symptomatic age, likely contributing to the oxidative stress and apoptosis phenotypes observed. Finally, an increased incidence of blood retention in SMA hearts post-fixation suggests the likelihood of functional defects, resulting in blood pooling. These pathologies mirror dilated cardiomyopathy, with clear consequences for heart function that would likely contribute to potential heart failure. Our findings add significant additional experimental evidence in support of the requirement to develop systemic therapies for SMA capable of treating non-neuromuscular pathologies.
Introduction
Our understanding of the pathogenesis of spinal muscular atrophy (SMA) remains incomplete, despite its classification as a single gene disorder and a major genetic cause of infant mortality. The ubiquitously expressed survival motor neurone protein (SMN) -named due to the predominant motor neurone loss seen in SMA (Werdnig, 1891; Hoffmann, 1892 ) -is produced from two genes in humans, with the majority of full-length protein produced by the SMN1 gene (Lorson et al. 1999) . In SMA, an autosomal recessive disease, mutations in the SMN1 gene leave the SMN2 gene alone to produce small amounts of full-length, functional SMN protein (Lefebvre et al. 1995) . This is sufficient to prevent embryonic lethality but results in the pathology of SMA.
SMA is primarily characterised by loss of ⍺-motor neurones in the spinal cord, causing denervation and resulting atrophy of skeletal muscle (Lunn & Wang, 2008; Powis & Gillingwater, 2016) . However, a range of non-neuromuscular pathologies are also now apparent (reviewed in: Hamilton & Gillingwater, 2013; Shababi et al. 2014; Nash et al. 2016) , including abnormalities affecting the liver (Vitte et al. 2004; Szunyogova et al. 2016) , lung (Schreml et al. 2013) , pancreas (Bowerman et al. 2012 (Bowerman et al. , 2014 , spleen (Thomson et al. 2016; Deguise et al. 2017; Khairallah et al. 2017) , testis (Ottesen et al. 2016) , intestines (Sintusek et al. 2016 ) and the vascular system (Shababi et al. 2012; Somers et al. 2012 Somers et al. , 2016 Sintusek et al. 2016) . Among these, cardiac abnormalities were first putatively described in SMA patients~60 years ago (Sterne & Lavieuville, 1964; Gardner-Medwin et al. 1967) but are only now becoming accepted as a potentially core aspect of SMA, particularly in severe forms of the disease (Wijngaarde et al. 2017) .
In patients, cardiac defects have been described across mild and severe forms of SMA, commonly falling into two major categories: structural defects and arrhythmias. Congenital heart defects, including atrial septal defects, ventricular septal defects and hypoplastic aortic arch, are the most common structural defects observed in SMA patients (Møl-ler et al. 1990; B€ urglen et al. 1995; Mulleners et al. 1996; Jong et al. 1998; El-Matary et al. 2004; Cook et al. 2006; Sarnat & Trevenen, 2007; Vaidla et al. 2007; Menke et al. 2008; Araujo et al. 2009; Grotto et al. 2016; Krupickova et al. 2017) . However, pulmonary hypertension, ventricular enlargement, systolic murmurs and cardiomyopathies have also been reported (Tanaka et al. 1976 (Tanaka et al. , 1977 Kimura et al. 1980; Møller et al. 1990; Distefano et al. 1994; Elkohen et al. 1996; Finsterer & St€ ollberger, 1999; El-Matary et al. 2004; Collado-Ortiz et al. 2007; Vaidla et al. 2007; Menke et al. 2008; Kuru et al. 2009 ). In the case of arrhythmias, bradycardias are most predominant in children with SMA, although heart block and ECG tremors have also been noted (Tanaka et al. 1976; Kimura et al. 1980; Dawood & Moosa, 1983; Coletta et al. 1989; Finsterer & St€ ollberger, 1999; Arai et al. 2005; Hachiya et al. 2005; Takahashi et al. 2006; Rudnik-Sch€ oneborn et al. 2008; Roos et al. 2009; Haliloglu et al. 2015; Grotto et al. 2016) . Together these findings do not immediately suggest a common or consistent aetiology. Therefore, further work is required to understand the degree to which these represent primary or secondary causative co-morbidities.
Heart defects have been reliably reproduced in both severe and mild mouse models of SMA. These include structural changes represented by thinning of the interventricular septum (IVS) and left ventricular (LV) wall (Shababi et al. 2010; Schreml et al. 2013; Bogdanik et al. 2015) ; dilated cardiomyopathy (Bevan et al. 2010; Heier et al. 2010; Schreml et al. 2013; Bogdanik et al. 2015) ; and increased fibrosis and oxidative stress (Shababi et al. 2010) . In both severe and mild mouse models, reports of both a decreased ejection fraction (Bevan et al. 2010; Bogdanik et al. 2015) and arrhythmias, particularly bradycardia (Bevan et al. 2010; Heier et al. 2010; Shababi et al. 2010; Biondi et al. 2012; Bogdanik et al. 2015) , indicate functional changes. Significantly, in the very mild 'Burgheron' mouse model, some mice die from severe cardiomyopathy rather than the effects of neuromuscular pathology (Bogdanik et al. 2015) . However, our understanding of these heart defects is still incomplete.
Heart defects in SMA represent only one aspect of disruption to the cardiovascular system. Other notable changes include a pronounced decrease in blood vessel density in skeletal muscle of both patients and a severe mouse model (Somers et al. 2012 , and in the spinal cord , intestines (Sintusek et al. 2016 ) and heart (Shababi et al. 2012 ) of severe SMA mouse models. Distal necrosis is seen in the fingers and toes of patients (Araujo et al. 2009; Rudnik-Sch€ oneborn et al. 2010) and in the ears and tail of mouse models (Hsieh-Li et al. 2000; Tsai et al. 2006; Narver et al. 2008; Riessland et al. 2010; Hua et al. 2011; Schreml et al. 2013; Bogdanik et al. 2015; Catapano et al. 2016) . This necrosis in patients is resolved by anticoagulant treatment, suggesting that these are thrombotic occlusions (Araujo et al. 2009 ). Finally, there is consistent evidence of persistent extramedullary haematopoiesis in SMA. In a severe mouse model, the liver is undergoing erythropoiesis; it has an increased number of megakaryocytes; elevated platelet levels; and higher levels of normoblasts (nucleated red blood cells) in blood samples (Szunyogova et al. 2016) . Similarly, the spleen of a severe SMA mouse also has increased megakaryocyte density and immature architecture indicative of ongoing haematopoiesis (Thomson et al. 2016) . Abnormalities of the spleen have also been reported in SMA patients, with red pulp congestion and the presence of erythroid precursors (Thomson et al. 2016) .
Given the growing awareness of cardiovascular defects in SMA, we set out to undertake a detailed morphological assessment of the heart in the 'Taiwanese' mouse model of severe SMA. By focusing on the period between birth and the first appearance of overt neuromuscular symptoms, we attempted to identify the initiation of cardiovascular defects, giving a better understanding of mechanisms underlying these phenotypes in SMA.
We report significant structural and molecular defects in the heart prior to or in tandem with overt neuromuscular pathology; key molecular targets of SMN-depletion in the heart; and suggest a multifactorial cardiovascular system pathology.
Methods Mice
The Taiwanese SMA mouse model on a congenic FVB background was used to replicate a severe phenotype of SMA. Taiwanese SMA mice were maintained as breeding pairs under standard specificpathogen-free conditions in animal care facilities at Edinburgh University (Hsieh-Li et al. 2000; Riessland et al. 2010; Powis et al. 2016b) . Offspring littermates were either heterozygous for Smn knockout (Smn ) and used as an SMA disease model. All experimental protocols were approved by Edinburgh University internal research and ethics committees and were carried out in accordance with licences obtained from the United Kingdom Home Office under the Animals (Scientific Procedures) Act 1986. Genotyping of mice was carried out via standard PCR protocols (Wishart et al. 2014) . Day of birth is defined as postnatal day 1 (P1).
Tissue processing
Hearts were harvested between P1-P8 from mice sacrificed by intraperitoneal injection of sodium pentobarbital in accordance with UK guidance and rules for the use of animals in research. Hearts were then fixed for 4 h in 4% paraformaldehyde (PFA) before undergoing cryoprotection in 30% sucrose and embedding in OCT. Hearts were cryo-sectioned at a thickness of 7 lm. Sections then underwent either basic haematoxylin and eosin (H&E) staining or immunohistochemistry.
Immunohistochemisty
Heart sections were incubated overnight at 4°C with the following primary antibodies: rabbit polyclonal anti-Collagen IV (Millipore, AB756P), rabbit polyclonal anti-Ki67 (Abcam, ab16667) and rat monoclonal anti-Ly76 (Abcam, ab91113); and for 2 h with the corresponding secondary antibodies: Cy3 goat anti-rabbit IgG (H+L) (Life Technologies, A-10520) and Cy3 goat anti-rat IgG (H+L) (Life Technologies, A-10522). Washes for 3 9 10 min in PBT [0.1 M phosphate buffered saline (PBS) with 0.1% Tween-20] and 0.1 M PBS were carried out between and after antibody incubation. Rhodaminelabelled Griffonia Lectin 1 (GSL-1) was used to stain vasculature. Sections were coverslipped using mowiol mounting media [10% Mowiol (Sigma-Aldrich, 81381), 20% glycerol, 50% 0.2 M Tris buffer pH 8.5, 3% 1,4-diazobicyclooctane made up in distilled water] containing 4',6-diamidino-2-phenylindole (DAPI). Sections were imaged using Nikon eclipse e400 microscope (109 objective) and its images captured using QICAM Fast 1394 camera and IMPROVISION VELOCITY 4 image capture software.
Quantitative Western blotting
Quantitative Western blotting was carried out on three hearts per genotype (Eaton et al. 2014) . Briefly, hearts were digested in RIPA buffer containing 2.5% Halt protease inhibitor cocktail and homogenised. BCA assay was carried out to quantify protein concentration of individual samples. Protein 15 lg was loaded per well. Samples were separated by electrophoresis on precast Bolt TM 4-12% Bis-Tris Plus Gels (NW04120BOX) and then transferred to nitrocellulose membranes using semi-dry I-Blotâ transfer system (Invitrogen, UK). Reversible total protein stain was carried out using Li-COR Revert total protein stain and wash solution (LI-COR, 926-11011). To revert the membrane, 0.1% sodium hydroxide in 30% methanol in water was used. Membranes were incubated overnight at 4°C with the following primary antibodies: rabbit polyclonal anti-caspase-3 (Abcam, ab13847), rabbit polyclonal antiangiotensin II receptor 1 (AT-1) (Abcam, ab18801) and goat polyclonal anti-platelet endothelial cell adhesion molecule-1 (PECAM-1) (R&D Systems, AF3628); diluted in SeaBlock blocking buffer (ThermoFisher Scientific, 37527) with Tween-20. Corresponding secondary antibodies, donkey anti-rabbit Alexa Fluorâ 680 IgG (H+L) (Abcam, ab186692) and donkey anti-goat Alexa Fluorâ 790 IgG (H+L) (Abcam, ab175784), were incubated at room temperature for 2 h. Washes for 6 9 10 min with 0.1 M PBS were carried out between and after antibody incubation. Membranes were imaged using Li-COR Odyssey Scanner and Software. Due to alterations in the expression levels of many standard loading control proteins in SMA tissues, total protein was used to normalise protein expression (Eaton et al. 2013) . Image Studio Lite was used for quantification of Western blots.
Heart quantification
In all analyses, folded or damaged heart sections were rejected. IMA-GEJ was used to measure the area of the heart and ventricles for cell counts, and for red blood cell density analysis. A protractor generated in Adobe PHOTOSHOP was used to quantify IVS and LV walls.
Quantification of structural changes to the heart IVS width, LV wall width and ventricular lumen area were measured from 4 H&E-stained slides, containing about eight heart sections per heart (~30 in total per heart), from the same relative area, i.e. between the apex and the atrioventricular septum. Images were captured at 409 magnification and under the same exposure. The freehand selection tool in IMAGEJ was used to measure the area of the heart and the left and right ventricles in calibrated images. In Adobe PHOTOSHOP, to measure the IVS and the LV wall, the largest rectangle of best fit was placed in the LV and the centre was found. From here, lines of 20°were drawn radially to intersect the IVS or LV wall and the ruler tool was used to measure the distance between points on these lines. Distance was either measured between the edge of the two ventricles for IVS width or between the left ventricle wall and the edge of the heart for LV wall width.
Ly76 density quantification
The density of Ly76-positive cells was measured from about eight sections taken from the same relative area in each heart. Images were captured at 409 magnification and under the same exposure. Brightness and contrast were enhanced in Adobe PHOTOSHOP. The enhanced images were then converted into binary in IMAGEJ, where Ly76-positive cells were assigned as black and the background aswhite. A ratio of black to white pixels for the whole heart area could then be calculated, allowing a relative value for Ly76-positive cell area relative to heart area, expressed as a percentage.
Cell density and Ki67-positive cell quantification
Cell density was calculated from about eight sections at the same relative area in each heart. From each heart section, six different images at 4009 magnification were captured fully composed of tissue at the same exposure, from the same six areas for each heart, i.e. in the LV wall, the IVS and the RV wall. DAPI-blue channels and Ki67-red channels were merged in Adobe PHOTOSHOP. IMAGEJ was then used to count the number of DAPI-positive nuclei only, and both DAPI-and Ki67-positive nuclei combined in the field of view. The number of Ki67-and DAPI-positive cells combined was expressed as a percentage of total number of DAPI-positive cells.
Statistics
All experimental groups consisted of a minimum of three different animals, which has previously been shown to be sufficient to attain statistical significance (Szunyogova et al. 2016) . All graphs are shown as mean AE SEM. Unpaired two-tailed t-test and two-way ANOVA were carried out using PRISM, where * < P0.05, ** < P0.01 and *** P < 0.001.
Results
Gross heart morphology is altered in SMA mice Initial assessment of hearts from SMA mice revealed no obvious gross anatomical disorganisation across all ages studied from P1 and P3 (pre-symptomatic), through P5 (early symptomatic) and P8 (symptomatic), but SMA hearts were smaller when compared with control (Fig. 1A) . When heart weight was expressed relative to bodyweight (which is lower in late symptomatic SMA mice; see Powis et al. 2016b) , there was no significant difference between SMA and control hearts at any of the ages examined (P1, 3, 5, 8: ns P > 0.05: Fig. 1B) .
Upon closer observation of transverse sections of the heart stained with H&E, SMA hearts appeared to have thinner ventricular walls, and larger ventricles, which were congested with blood (Fig. 1C) . IVS and LV wall measurements have been made previously (Bevan et al. 2010; Shababi et al. 2010) ; however, the time course of ventricle dilation has not been analysed. Quantification revealed that the relative area of the heart comprising the ventricles was significantly greater in SMA, at pre-(P3) and early (P5) symptomatic ages, suggesting that enlargement of the ventricles occurs early in the SMA phenotype (P1: ns P > 0.05; P3: *** P < 0.001; P5: * P < 0.05) (Fig. 1D) . Furthermore, the IVS and LV wall, which together make up the main muscle mass of the heart, were thinner, relative to bodyweight, in SMA hearts from an early age (Fig. 1E,F) . The IVS was significantly thinner at pre-and early symptomatic ages (P1: ns P > 0.05; P3: * P < 0.05; P5: ** P < 0.01), whereas the LV wall was significantly thinner from birth onwards (P1: * P < 0.05; P3: *** P < 0.001; P5: * P < 0.05).
These data not only show significant changes in the heart wall and IVS in the Taiwanese SMA mouse model but moreover indicate that they develop in pre-symptomatic animals, with evidence of cardiac defects present at birth. This suggests that heart pathology is likely to represent a primary event in SMA and is not simply a secondary consequence of neuromuscular pathology. Cross-sectional area of both ventricles, expressed as a percentage of total crosssectional area of heart in control and SMA mice at birth (P1), pre-symptomatic (P3) and early symptomatic (P5) ages. (E) Width of interventricular septum (IVS) in relation to bodyweight of control and SMA mice at birth (P1), pre-symptomatic (P3) and early symptomatic (P5) ages. (F) Width of LV wall in relation to bodyweight of control and SMA mice at birth (P1), pre-symptomatic (P3) and early symptomatic (P5) ages. Error bars: mean AE SEM (n ≥ 3 mice per group). A twoway ANOVA was used to calculate P-values; * P < 0.05, ** P < 0.01, *** P < 0.001.
Cardiomyocytes are disorganised in the SMA heart
Given the gross pathology evident in the heart wall of SMA mice, we next investigated the fine structure of the heart to determine the likely aetiology of the defects in the IVS and LV wall. To determine the arrangement of cardiomyocytes, collagen IV immunohistochemistry was used to highlight surrounding basement membranes from birth to early symptomatic ages (P1, P3 and P5). The basement membrane surrounds the cardiomyocytes providing structural support and is important during heart development for the formation of sarcomeres.
At P5 the LV wall in control hearts was clearly formed by three layers of cardiac muscle; superficial oblique, cylindrical middle and deep longitudinal layers ( Fig. 2A v and B i) . The middle layer in particular was most pronounced, containing strands of cardiomyocytes which spiralled out anti-clockwise from the LV, twisting in conjunction with heart contraction (Greenbaum et al. 1981; Sedmera & McQuinn, 2008 ). This structure not only ensures a coherent electrical impulse transfer but is essential for the twisting motion of the ventricles observed during contraction of the heart. At birth, this spiral structure surrounding the LV was beginning to develop in the control heart ( Fig. 2A i) . In contrast, the heart wall in SMA was disorganised with no apparent development of cardiomyocyte orientation between birth and P5 ( Fig. 2A ii, A iv, A vi and B ii). The appearance was in fact similar to an embryonic heart, where muscle is arranged circumferentially around the ventricle rather than radiating from it (Sedmera & McQuinn, 2008) .
During embryonic development, trabeculations are formed in the ventricles prior to the formation of the coronary vasculature to increase surface area for nutrient uptake (Sedmera et al. 2000 ). An essential stage in increasing the mass of the compact muscular wall of the heart is compaction of these trabeculae, which coincides with the formation of the coronary blood supply (Sedmera et al. 2000) . In the control heart, nearer the luminal wall of the LV, trabeculations can often be seen. These trabeculations are sparse, do not penetrate far into the lumen, and appear large enough to allow the growth of a blood supply to these cells (Fig. 2B iii) . In SMA, these trabeculations were greater in number, projected further into the lumen, and were very thin, with little capacity for a blood supply to invade (Fig. 2B iv) . This occurred from birth, where P1 SMA hearts had little definition between the compact wall and the ventricles ( Fig. 2A ii) , and this lack of definition was still present at early symptomatic (P5) ages ( Fig. 2A vi) .
Collagen IV immunostaining, used to visualise cardiomyocyte arrangement, showed a non-uniform pattern of labelling with an apparent decrease in staining, particularly towards the superficial surface in the SMA hearts compared with control hearts. This suggests a defect in the basement membrane, of which collagen IV is a key component and which is essential to maintain the organisation of cardiomyocytes in the heart. Further, a significant global decrease in collagen IV expression in SMA hearts was demonstrated by quantitative Western blotting at birth (P1: * P < 0.05) (Fig. 2C) . Importantly, collagen IV interacts directly with SMN protein (Fuller et al. 2016) , suggesting a potential mechanistic link between SMN depletion and heart wall disorganisation.
SMA hearts have a decreased number of cardiomyocytes associated with increased apoptosis
To establish the cellular basis of the changes in SMA heart structure, cardiomyocytes were specifically investigated from birth (P1) through to early symptomatic ages (P5). SMA hearts showed a significant decrease in cardiomyocyte number per unit area (density) at pre-(P3) and early (P5) symptomatic ages but not at birth (P1: ns P > 0.05; P3: ** P < 0.01; P5: *** P < 0.001) (Fig. 3B) . To establish the nature of this decrease in cardiomyocyte density, cell proliferation and apoptosis were analysed. Heart sections were stained with Ki67 (Fig. 3A) , a proliferation marker expressed during all phases of division (Scholzen & Gerdes, 2000) ; however, no significant difference in the number of proliferating cells between control and SMA was observed between birth and P5 (P1: ns P > 0.05; P3: ns P > 0.05; P5: ns P > 0.05) (Fig. 3C) . Apoptosis was analysed by Western blot for caspase-3, involved in the activation cascade of caspases responsible for apoptosis execution (Porter & J€ anicke, 1999) , which showed a significant increase in early symptomatic SMA hearts (P1: ns P > 0.05; P3: ns P > 0.05; P5: **P < 0.01) (Fig. 3D ). This suggests that the decrease in cardiomyocyte density may be linked to an increase in cell death consistent with atrophy of the heart.
Oxidative stress is present in SMA hearts
Increased apoptosis in cardiomyocytes was investigated further by examining a common trigger, oxidative stress, which is present in D7 SMA mice exhibiting a neuromuscular phenotype (Shababi et al. 2010 ). We analysed angiotensin II receptor 1 (AT1) levels as a marker of oxidative stress in the heart, as this increases ROS by elevating the activity of NADPH oxidase during heart failure (Qin et al. 2005) . Immunohistochemistry showed dramatically increased amounts of AT-1 in the SMA heart at birth compared with the control heart (Fig. 4A) . Western blot analyses confirmed these higher levels of AT-1 in SMA compared with control hearts at both P3 and P5 (P1: ns P > 0.05; P3: *P < 0.05; P5: ** P < 0.01) (Fig. 4A) , indicating the presence of oxidative stress in SMA hearts with onset at a pre-symptomatic age.
To substantiate this finding we looked for evidence of mitochondrial-derived oxidative stress, as multiple proteins in the mitochondria are associated with increased ROS production (Mart ınez- Reyes & Cuezva, 2014) . This includes the ATP synthase complex, which interacts directly with SMN (Fuller et al. 2016) . We analysed levels of subunit 6 of the ATP synthase complex as mutations or overexpression of this subunit are particularly associated with oxidative stress (Manczak et al. 2005; Jonckheere et al. 2012) . Western blot analyses showed significantly higher levels of MT-ATP6 in SMA at birth compared with controls (P1: *P < 0.05) (Fig. 4B) .
The presence of increased oxidative stress at birth not only suggests this is an important event in the aetiology of SMA heart pathology but is also indicative of early mitochondrial dysfunction. As oxidative stress is present prior to increased caspase-3 expression, and significantly occurs prior to the appearance of neuromuscular symptoms, it is likely to precede and contribute to cardiomyocyte apoptosis and heart dysfunction.
SMA heart microvasculature is significantly decreased
A reduction in capillary density has been reported across multiple tissues in SMA patients and animal models, where it is associated with tissue hypoxia . Previously, decreased microvasculature in the heart of the D7 SMA mouse model has only been studied at a late symptomatic age. Here, microvasculature was analysed at early and pre-symptomatic ages to establish whether it might contribute to, rather than be a symptom of, heart pathology. Immunostaining of hearts with GSL-1 endothelial cell marker indicated a gross decrease in microvasculature density throughout the heart wall particularly at P5 in SMA (Fig. 5A,B) . Western blot for a second endothelial cell marker, PECAM-1, as used previously (Somers et al. 2012 , confirmed a significantly decreased expression Unpaired Student's two-tailed t-test was used to calculate P-values; * P < 0.05. Fig. 3 SMA hearts have a decreased number of cardiomyocytes and an increase in apoptosis. (A) Panels show co-immunostaining of nuclei of the cardiomyocytes with DAPI (blue) and Ki67 (red) to indicate dividing cells in control and SMA hearts, at birth (P1), pre-symptomatic (P3) and early symptomatic (P5) ages, at low (i, ii) and high power (iii, iv). Scale bar: 50 lm. (B) Cardiomyocyte cell density, from nuclear counts, expressed per field of view in control and SMA hearts, at birth (P1), pre-symptomatic (P3) and early symptomatic (P5) ages. (C) Dividing cells (Ki67-positive nuclei) expressed as a percentage of the total number of nuclei per field of view in control and SMA hearts, at birth (P1), pre-symptomatic (P3) and early symptomatic (P5) ages. (D) Quantitative Western blot showing total levels of caspase-3 in control and SMA hearts, at birth (P1), pre-symptomatic (P3) and early symptomatic (P5) ages. Error bars: mean AE SEM (n ≥ 3 mice per group). Unpaired Student's two-tailed t-test and a two-way ANOVA were used to calculate P-values; ** P < 0.01, *** P < 0.001.
in SMA heart at an early symptomatic age (P5) (P1: ns P > 0.05; P3: ns P > 0.05; P5: *P < 0.05) (Fig. 5C ). This decrease in heart wall microvasculature was particularly apparent at high magnification in the wall immediately adjacent to the ventricular lumen (Fig. 5B) . This early contributing factor to cardiac defects is likely to result in hypoxia of cardiomyocytes, similar to that seen at P5 in the spinal cord of the SMA mouse, and may exacerbate increased cell death.
SMA hearts are congested with blood
The hearts used in this study were not perfused prior to fixation. Therefore, residual blood left in the heart after removal is likely a reflection of functional circulatory conditions. In our initial observations of histologically stained hearts, it was apparent that SMA hearts contained more blood than hearts of the controls (Fig. 1C) . To examine this increase further, we stained red blood cells (RBCs) with Ly76 (which labels all cells in the erythrocyte lineage including RBCs). Ly76 marker showed that heart chambers viewed in cross-sections of P5 control hearts have only small amounts of blood, whereas SMA hearts are congested with blood, which is most apparent in the ventricles (Fig. 6A) . Quantification of Ly76 stain showed a significant (two-to three-fold) increase in the RBCs in SMA hearts at both pre-and early symptomatic ages compared with controls (P1: ns P > 0.05; P3: *P < 0.05; P5: *P < 0.05) (Fig. 6B) . This is consistent with a model where the structural and molecular defects previously observed, impact negatively on heart function, resulting in blood pooling. Fig. 4 Oxidative stress is present in SMA hearts. (A) Immunostaining of heart wall at P1 showing the presence of AT-1 immunoreactivity in the SMA (ii), but not the Control (i) heart. (B) Quantitative Western blot showing the total levels of angiotensin II receptor 1 (AT-1) in control and SMA hearts, at birth (P1), pre-symptomatic (P3) and early symptomatic (P5) ages. (C) Quantitative Western blot showing total levels of mitochondrial ATPsynthase FO subunit 6, at birth (P1) in control and SMA hearts. Error bars: mean AE SEM (n ≥ 3 mice per group). Unpaired Student's two-tailed t-test was used to calculate P-values; * P < 0.05, ** P < 0.01.
Discussion
Here, we show that Taiwanese SMA mouse hearts have thinner muscular walls, with disorganised basement membranes and cardiomyocytes present pre-symptomatically. Cardiomyocytes were decreased in density, likely due to increased apoptosis, at an early symptomatic age, which is associated with increased oxidative stress from birth and also decreased microvasculature in the heart at an early symptomatic age. This demonstrates that heart defects are an early and important feature of disease pathogenesis in SMA.
The decrease in IVS and LV wall width described here is consistent with findings from other mouse models and may be linked to congenital heart defects such as septal defects between both atria and ventricles in SMA patients. IVS thinning was present from 3 days postnatally, suggesting a failure to adapt to the radical pressure changes that occur after birth (Rein et al. 1987) . LV wall thinning was observed pre-symptomatically at birth, likely affecting heart function and therefore systemic blood flow. Taken together, these findings point toward impaired development of the SMA heart as a significant contributor to cardiovascular defects.
Enlarged ventricles contribute to heart dysfunction in SMA hearts
Enlargement of the ventricles is commonly linked to dilation and dysfunction of the heart, particularly in combination with thinning of the heart walls (Redfield et al. 2003) . This is consistent with the cardiac phenotype described here in SMA, where dilation of the ventricles is a secondary event, occurring at P3 after the primary event of a decrease in LV wall width at P1. This dilation phenotype correlates with previous studies showing a decreased ejection fraction in mouse SMA hearts (Bevan et al. 2010; Bogdanik et al. 2015) , with cardiac defects, including dilation of atria and ventricles, diastolic dysfunction and ventricular overload seen in SMA patients (Tanaka et al. 1976; Kimura et al. 1980; Distefano et al. 1994; Elkohen et al. 1996; Finsterer & St€ ollberger, 1999; Collado-Ortiz et al. 2007; Menke et al. 2008; Kuru et al. 2009; Grotto et al. 2016) . Taken together, thinning of the walls and enlargement of the ventricles in the SMA heart is strikingly similar to dilated cardiomyopathy (DCM), where the heart becomes enlarged and cannot pump blood efficiently, evidenced by blood pooling. These defects will likely result in systolic heart failure (Maron et al. 2006) , which has been reported in some SMA patients (Collado-Ortiz et al. 2007 ).
Cardiomyocytes are disorganised in SMA hearts
Our findings suggest that gross abnormalities in the SMA heart are underpinned by cellular defects, likely driven by SMN depletion in the cardiomyocytes. Collagen IV levels were decreased in SMA, likely affecting cardiomyocyte organisation through its role in basement membrane structure (Lundgren et al. 1988) . The basement membrane maintains cardiomyocyte shape (Lundgren et al. 1988) ; anchors them to the ECM (Zellner et al. 1991) ; regulates their electrical properties (Frank et al. 1977; Yang et al. 2014) ; regulates sarcomeric formation and remodelling (Ross & Borg, 2001; Yang et al. 2015) ; and influences force production (Factor & Robinson, 1988; Yang et al. 2015) . Specifically, the collagen IV network increases rigidity and strength, resulting in a more fluid and powerful contraction (Bruggink et al. 2007 ).
This defective basement membrane and abnormal organisation of cardiomyocytes will likely impair electrical conduction through end-to-end gap junctions (Zellner et al. 1991) , preventing a coherent contraction through the heart (Greenbaum et al. 1981; Sedmera & McQuinn, 2008) . In addition, trabeculae are more common in SMA hearts and the cardiac muscle is circumferentially rather than spirally oriented, both of which suggest that the heart wall is not maturing correctly in the embryonic period. Compaction of trabeculae contributes to the thickness of the ventricular and IVS muscular mass, the papillary muscles, vasculature and the conduction system (Sedmera et al. 2000) . The failed compaction seen in the SMA heart may underlie septal defects and arrhythmias seen in SMA patients.
Oxidative stress is present in SMA hearts
In parallel with the structural defects described above, the pre-symptomatic increases in AT-1 and MT-ATP6 reported here suggest that oxidative stress is present in the SMA heart, and that it precedes increased cardiomyocyte death. Oxidative stress is thought to be critical for the activation of apoptosis, including caspase activation, in failing hearts (Cesselli et al. 2001) . AT-1 is also increased in the heart of the D7 SMA mouse model (Shababi et al. 2010) , which points to oxidative stress as a common mechanism in SMA cardiovascular pathology. In our study, caspase levels did not correlate perfectly with cardiomyocyte density, which is likely due to the high variability in proliferation of cardiomyocytes, particularly at P3, contributing to the decrease in cell number prior to the increase in cell death.
As ATP synthase subunits interact directly with SMN protein and are overexpressed in the CNS of multiple SMA models, there is a potentially direct mechanistic link between SMN depletion and cardiac dysfunction (Fuller et al. 2016) . Taken further, defects in mitochondria, including fragmentation of the mitochondrial network, impaired mitochondrial membrane potential and increased oxidative stress are all thought to be associated with motor neurone cell death in SMA (Acsadi et al. 2009; Miller et al. 2016; Ripolone et al. 2015; Xu et al. 2016; Boyd et al. 2017) . Cardiomyocytes contain many mitochondria (more than skeletal muscle) to support their high-energy demands (Hom & Sheu, 2009) and are therefore highly susceptible to mitochondrial dysfunction-mediated oxidative stress. Swollen and degenerating mitochondria are seen in cardiomyocytes in late symptomatic SMND7 mice (Bevan et al. 2010) , which is consistent with late-stage heart failure. Here, however, we show that the changes in the level of a mitochondrial-specific protein, MT-ATP6, are already present at birth, suggesting that mitochondrial dysfunction may be a primary driver of cardiac defects in SMA.
Blood pools in the ventricles of SMA hearts
The thin heart walls in SMA are likely to contract less efficiently, resulting in a decreased ejection fraction (Bevan et al. 2010; Bogdanik et al. 2015) , blood pooling (Ghio et al. 2001) , additional stress, increased cell death and a positive feedback loop, ultimately leading to heart failure (Narula et al. 1996) . However, the heart is a dynamic organ and abnormal blood flow through the heart, altered by forces including preload and afterload (Bugge-Asperheim & Kiil, 1973) , could also contribute to blood pooling. In addition, extrinsic factors such as altered blood composition, including that resulting from abnormal erythropoiesis and platelet production in the SMA liver (Szunyogova et al. 2016) , will impact on blood flow and contribute to ventricular distension. These alterations in blood flow and observations of blood pooling could also explain the pulmonary hypertension and pulmonary effusion reported in SMA patients (Møller et al. 1990; Distefano et al. 1994; El-Matary et al. 2004; Menke et al. 2008) . Here, we propose a model to interpret the cardiac defects observed (Fig. 7) .
With a new treatment for SMA, Spinraza (Nusinersen), approved by the FDA and EMA, it is now critically important showing GSL-1 only (red) (i, ii) and merged with DAPI nuclei (blue) (iii, iv). Scale bar: 50 lm. (C) Quantitative Western blot showing total PECAM-1 level in control and SMA hearts, at birth (P1), pre-symptomatic (P3) and early symptomatic (P5) ages. Error bars: mean AE SEM (n ≥ 3 mice per group). Unpaired Student's two-tailed t-test was used to calculate P-values; * P < 0.05.
to understand these cardiovascular pathologies. The drug is administered intrathecally and therefore only targets the central nervous system (Hoy, 2017 ), which appears to limit its utility in disease treatment (Finkel et al. 2017 ). Conversely, an as yet unapproved, systemically administered gene therapy may offer hope of obtaining significant patient benefit (Mendell et al. 2017 ) by treating the disease as a whole. Consequently, it is an unfortunate possibility that cardiovascular defects may be uncovered in these treated SMA patients.
Conclusion
In conclusion, the severe Taiwanese SMA mouse model has severe cardiac defects from birth. Thinning of the IVS and dilation of ventricular lumens was seen from pre-symptomatic ages through until late symptomatic stages of disease. Most significantly, changes in the LV width were observed from birth, prior to motor neurone pathology. There were also changes in the organisation of cardiomyocytes from birth in SMA, which may be linked to altered levels of basement membrane protein collagen IV; increased oxidative stress in cardiomyocytes pre-symptomatically; increased apoptosis of cardiomyocytes seen at early symptomatic ages; decreased microvasculature also at an early symptomatic age; and increased blood pooling within the SMA heart ventricles at a pre-symptomatic age. This combines to suggest a phenotype similar to dilated cardiomyopathy that will most likely lead to heart failure. It is therefore essential to develop systemic therapies for SMA capable of treating cross-sectional area of the heart in control and SMA, at birth (P1), pre-symptomatic (P3) and early symptomatic (P5) ages. Error bars, mean AE SEM (n ≥ 3 mice per group). A twoway ANOVA was used to calculate P-values; * P < 0.05. these cardiac pathologies, in addition to the well-established neuromuscular defects.
